Standard BioTools Inc.: financial analysis
Ratios worked out from 10 fiscal years of Standard BioTools Inc.'s statements, compared with 670 companies in Biotechnology.
Standard BioTools Inc. scorecard#
Passes 5 of the 21 checks that could be worked out: strongest in valuation (4 of 5), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation4 of 5
- ✓P/E below its peers' median1.8×P/E 1.8× against Biotechnology's median of 16.9×.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.8×.
- ✓Price to sales below its peers' median2.9×Price to sales 2.9× against Biotechnology's median of 8.6×.
- ✗Free cash flow yield above 5%-33.8%Free cash flow is -33.8% of the market value.
- ✓Earnings yield above the 10-year Treasury yield54.3%Earnings yield 54.3% against the 10-year Treasury's 4.92% on 2026-11-20.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-6.2%Revenue down 6.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-4.5%-4.5% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-4.5%-4.5% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.20 vs -0.52Diluted EPS -0.20 in fiscal 2025 against -0.52 the year before (report's currency).
- ✗Net income higher than five years earlier-$75 M-$75 M in fiscal 2025 against -$53 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$75 MNet income -$75 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-129.2%-129.2% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-16.7%-16.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-129.2%-129.2% in fiscal 2025 against -118.6% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.19 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-1.84Z-score -1.84 (distress zone) for fiscal 2025.
Shareholder returns0 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year8.0%Diluted shares up 8.0% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 6.2% against the year before.
- Net loss of $75 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$83 million.
- The share count rose 8.0% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin roseyes
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.61 | × 1.2 | 0.73 |
| Retained earnings to assets | -2.22 | × 1.4 | -3.11 |
| Operating income to assets | -0.19 | × 3.3 | -0.64 |
| Market value to liabilities | 1.71 | × 0.6 | 1.02 |
| Revenue to assets | 0.15 | × 1 | 0.15 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 49.9% | 49.3% | 47.4% | 37.8% | — | 74.8% | 24% | |
| Operating margin | -129.2% | -140.1% | -72.0% | -118.6% | -51.7% | -60.5% | 40% | |
| Net margin | -87.8% | -152.6% | -70.2% | -194.1% | -45.4% | -68.9% | 46% | |
| Return on equity | -16.7% | -85.8% | — | — | -50.7% | -61.0% | 82% | |
| Return on assets | -12.7% | -29.7% | -20.9% | -57.1% | -19.8% | -44.4% | 81% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.2% | -14.4% | 8.6% | -25.0% | -5.5% | 15.8% | 26% | |
| Revenue growth, 3 years a year | -4.5% | -11.3% | -8.4% | -5.8% | 5.0% | 12.9% | 26% | |
| Revenue growth, 5 years a year | -9.2% | -4.9% | -1.2% | -0.8% | 4.6% | 15.4% | 13% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | 0.00× | — | — | — | 0.26× | — | |
| Net debt | — | $-166 M | $12 M | $-16 M | — | $-16 M | — | |
| Interest cover | — | — | -16.76× | -26.84× | -17.66× | -22.77× | — | |
| Current ratio | 4.19× | 5.70× | 1.45× | 4.81× | 1.45× | 4.39× | 48% | |
| Equity share of assets | 74.7% | 77.0% | -45.8% | -20.9% | 34.4% | 64.3% | 61% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-83 M | $-152 M | $-46 M | $-93 M | $-57 M | $-40 M | 32% | |
| Free cash flow margin | -96.9% | -166.8% | -43.4% | -95.1% | -43.9% | -61.5% | 43% | |
| Capital spending share of revenue | 9.7% | 9.2% | 2.7% | 3.9% | 10.2% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.14× | 0.19× | 0.30× | 0.29× | 0.44× | 0.26× | 36% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).